GVK BIO, Endo enter research collaboration
GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development CRO, announced on Monday that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein.
Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA).
Manni Kantipudi, CEO of GVK BIO, said, "This collaboration also confirms the value of our differentiated EDATM concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates."
Dr. Sandeep Gupta, Endo's Senior Vice President of Drug Discovery and Early Development, stated: "We are pleased to initiate this discovery collaboration with GVK BIO. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients."